{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T01:10:25Z","timestamp":1776301825552,"version":"3.50.1"},"reference-count":215,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T00:00:00Z","timestamp":1663113600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Fundac\u00e3o para a Ci\u00eancia e a Tecnologia\/Minist\u00e9rio da Ci\u00eancia, Tecnologia e Ensino Superior","award":["2021.05081.BD"],"award-info":[{"award-number":["2021.05081.BD"]}]},{"name":"European Union through a PhD fellowship","award":["2021.05081.BD"],"award-info":[{"award-number":["2021.05081.BD"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Ovarian cancer (OC) has a specific type of metastasis, via transcoelomic, and most of the patients are diagnosed at advanced stages with multiple tumors spread within the peritoneal cavity. The role of Malignant Ascites (MA) is to serve as a transporter of tumor cells from the primary location to the peritoneal wall or to the surface of the peritoneal organs. MA comprise cellular components with tumor and non-tumor cells and acellular components, creating a unique microenvironment capable of modifying the tumor behavior. These microenvironment factors influence tumor cell proliferation, progression, chemoresistance, and immune evasion, suggesting that MA play an active role in OC progression. Tumor cells induce a complex immune suppression that neutralizes antitumor immunity, leading to disease progression and treatment failure, provoking a tumor-promoting environment. In this review, we will focus on the High-Grade Serous Carcinoma (HGSC) microenvironment with special attention to the tumor microenvironment immunology.<\/jats:p>","DOI":"10.3390\/ijms231810692","type":"journal-article","created":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T23:16:36Z","timestamp":1663197396000},"page":"10692","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Immune Tumor Microenvironment in Ovarian Cancer Ascites"],"prefix":"10.3390","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4270-7701","authenticated-orcid":false,"given":"Diana Lu\u00edsa","family":"Almeida-Nunes","sequence":"first","affiliation":[{"name":"Differentiation and Cancer Group, Institute for Research and Innovation in Health (i3S), Institute of Molecular Pathology and Immunology, University of Porto (IPATIMUP), 4200-135 Porto, Portugal"},{"name":"TOXRUN\u2014Toxicology Research Unit, University Institute of Health Sciences, CESPU, CRL, 4585-116 Gandra, Portugal"}]},{"given":"Ana","family":"Mendes-Frias","sequence":"additional","affiliation":[{"name":"Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, 4710-057 Braga, Portugal"},{"name":"ICVS\/3B\u2019s\u2014PT Government Associate Laboratory, 4710-057 Braga, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9270-2717","authenticated-orcid":false,"given":"Ricardo","family":"Silvestre","sequence":"additional","affiliation":[{"name":"Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, 4710-057 Braga, Portugal"},{"name":"ICVS\/3B\u2019s\u2014PT Government Associate Laboratory, 4710-057 Braga, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7430-6297","authenticated-orcid":false,"given":"Ricardo Jorge","family":"Dinis-Oliveira","sequence":"additional","affiliation":[{"name":"TOXRUN\u2014Toxicology Research Unit, University Institute of Health Sciences, CESPU, CRL, 4585-116 Gandra, Portugal"},{"name":"UCIBIO-REQUIMTE, Laboratory of Toxicology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, 4099-002 Porto, Portugal"},{"name":"Department of Public Health and Forensic Sciences, and Medical Education, Faculty of Medicine, University of Porto, 4099-002 Porto, Portugal"},{"name":"MTG Research and Development Lab, 4200-604 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4091-2226","authenticated-orcid":false,"given":"Sara","family":"Ricardo","sequence":"additional","affiliation":[{"name":"Differentiation and Cancer Group, Institute for Research and Innovation in Health (i3S), Institute of Molecular Pathology and Immunology, University of Porto (IPATIMUP), 4200-135 Porto, Portugal"},{"name":"TOXRUN\u2014Toxicology Research Unit, University Institute of Health Sciences, CESPU, CRL, 4585-116 Gandra, Portugal"},{"name":"Faculty of Medicine, University of Porto (FMUP), 4099-002 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"47","DOI":"10.21037\/cco-20-34","article-title":"Epidemiology of Ovarian Cancer","volume":"9","year":"2020","journal-title":"Chin. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1111\/cas.12987","article-title":"Ascites Modulates Cancer Cell Behavior, Contributing to Tumor Heterogeneity in Ovarian Cancer","volume":"107","author":"Kim","year":"2016","journal-title":"Cancer Sci."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"de Leo, A., Santini, D., Ceccarelli, C., Santandrea, G., Palicelli, A., Acquaviva, G., Chiarucci, F., Rosini, F., Ravegnini, G., and Pession, A. (2021). What Is New on Ovarian Carcinoma: Integrated Morphologic and Molecular Analysis Following the New 2020 World Health Organization Classification of Female Genital Tumors. Diagnostics, 11.","DOI":"10.3390\/diagnostics11040697"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"7439","DOI":"10.1158\/1078-0432.CCR-04-0683","article-title":"Recurrent Ovarian Cancer: How Important Is It to Treat to Disease Progression?","volume":"10","author":"Herzog","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/ncponc0637","article-title":"Ovarian Cancer: A Focus on Management of Recurrent Disease","volume":"3","author":"Herzog","year":"2006","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/S0002-9440(10)63708-X","article-title":"Ovarian Tumorigenesis: A Proposed Model Based on Morphological and Molecular Genetic Analysis","volume":"164","author":"Shih","year":"2004","journal-title":"Am. J. Pathol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"932371","DOI":"10.1155\/2010\/932371","article-title":"Ovarian Cancer Pathogenesis: A Model in Evolution","volume":"2010","author":"Karst","year":"2010","journal-title":"J. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2147\/IJWH.S197604","article-title":"Ovarian Cancer in the World: Epidemiology and Risk Factors","volume":"11","author":"Momenimovahed","year":"2019","journal-title":"Int. J. Women\u2019s Health"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2021\/5047501","article-title":"Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy Improves Survival with Acceptable Safety for Advanced Ovarian Cancer: A Clinical Study of 100 Patients","volume":"2021","author":"Zhang","year":"2021","journal-title":"BioMed Res. Int."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2217\/imt.11.20","article-title":"Immunity and Immune Suppression in Human Ovarian Cancer","volume":"3","author":"Preston","year":"2011","journal-title":"Immunotherapy"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/GCO.0000000000000340","article-title":"Pathogenesis and Heterogeneity of Ovarian Cancer","volume":"29","author":"Kroeger","year":"2017","journal-title":"Curr. Opin. Obstet. Gynecol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1200\/EDBK_174718","article-title":"Whence High-Grade Serous Ovarian Cancer","volume":"37","author":"Kohn","year":"2017","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/ijgo.12617","article-title":"Pathology of Cancers of the Female Genital Tract Including Molecular Pathology","volume":"143","author":"Prat","year":"2018","journal-title":"Int. J. Gynecol. Obstet."},{"key":"ref_14","first-page":"171","article-title":"Staging Classification for Cancer of the Ovary, Fallopian Tube, and Peritoneum","volume":"126","author":"Prat","year":"2015","journal-title":"Int. J. Gynecol. Obstet."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"787143","DOI":"10.1155\/2014\/787143","article-title":"BRCA-Associated Ovarian Cancer: From Molecular Genetics to Risk Management","volume":"2014","author":"Girolimetti","year":"2014","journal-title":"BioMed Res. Int."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Nwani, N.G., Sima, L.E., Nieves-Neira, W., and Matei, D. (2018). Targeting the Microenvironment in High Grade Serous Ovarian Cancer. Cancers, 10.","DOI":"10.3390\/cancers10080266"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"v23","DOI":"10.1093\/annonc\/mdq244","article-title":"Newly Diagnosed and Relapsed Epithelial Ovarian Carcinoma: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up","volume":"21","author":"Colombo","year":"2010","journal-title":"Ann. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3389\/fonc.2017.00024","article-title":"The Unique Molecular and Cellular Microenvironment of Ovarian Cancer","volume":"7","author":"Worzfeld","year":"2017","journal-title":"Front. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10147-012-0396-6","article-title":"Malignant ascites: Pathophysiology and treatment","volume":"18","author":"Cavazzoni","year":"2013","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_20","unstructured":"Chiejina, M., Kudaravalli, P., and Samant, H. (2022). Ascites. StatPearls, StatPearls Publishing."},{"key":"ref_21","first-page":"273","article-title":"Meeting the challenge of ascites in ovarian cancer: New avenues for therapy and research. Nature Reviews","volume":"13","author":"Kipps","year":"2013","journal-title":"Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.2353\/ajpath.2010.100105","article-title":"Ovarian Cancer Development and Metastasis","volume":"177","author":"Lengyel","year":"2010","journal-title":"Am. J. Pathol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Rickard, B.P., Conrad, C., Sorrin, A.J., Ruhi, M.K., Reader, J.C., Huang, S.A., Franco, W., Scarcelli, G., Polacheck, W.J., and Roque, D.M. (2021). Malignant Ascites in Ovarian Cancer: Cellular, Acellular, and Biophysical Determinants of Molecular Characteristics and Therapy Response. Cancers, 13.","DOI":"10.3390\/cancers13174318"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"9545","DOI":"10.3390\/ijms13089545","article-title":"Implication of Tumor Microenvironment in Chemoresistance: Tumor-Associated Stromal Cells Protect Tumor Cells from Cell Death","volume":"13","author":"Castells","year":"2012","journal-title":"Int. J. Mol. Sci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of Cancer: The next Generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ccr.2012.02.022","article-title":"Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment","volume":"21","author":"Hanahan","year":"2012","journal-title":"Cancer Cell"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s10585-016-9821-y","article-title":"Mesothelial Cells Interact with Tumor Cells for the Formation of Ovarian Cancer Multicellular Spheroids in Peritoneal Effusions","volume":"33","author":"Matte","year":"2016","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3389\/fonc.2013.00097","article-title":"Ovarian Tumor Attachment, Invasion, and Vascularization Reflect Unique Microenvironments in the Peritoneum: Insights from Xenograft and Mathematical Models","volume":"3","author":"Steinkamp","year":"2013","journal-title":"Front. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s10555-013-9456-2","article-title":"Ovarian Cancer Microenvironment: Implications for Cancer Dissemination and Chemoresistance Acquisition","volume":"33","author":"Thibault","year":"2014","journal-title":"Cancer Metastasis Rev."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Latifi, A., Luwor, R.B., Bilandzic, M., Nazaretian, S., Stenvers, K., Pyman, J., Zhu, H., Thompson, E.W., Quinn, M.A., and Findlay, J.K. (2012). Isolation and Characterization of Tumor Cells from the Ascites of Ovarian Cancer Patients: Molecular Phenotype of Chemoresistant Ovarian Tumors. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0046858"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/ijc.28335","article-title":"Mixed-Polarization Phenotype of Ascites-Associated Macrophages in Human Ovarian Carcinoma: Correlation of CD163 Expression, Cytokine Levels and Early Relapse","volume":"134","author":"Reinartz","year":"2014","journal-title":"Int. J. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1158\/0008-5472.CAN-11-2178","article-title":"A Dynamic Inflammatory Cytokine Network in the Human Ovarian Cancer Microenvironment","volume":"72","author":"Kulbe","year":"2012","journal-title":"Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/nrc3144","article-title":"Rethinking Ovarian Cancer: Recommendations for Improving Outcomes","volume":"11","author":"Vaughan","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"262","DOI":"10.18632\/oncoscience.31","article-title":"Acellular Fraction of Ovarian Cancer Ascites Induce Apoptosis by Activating JNK and Inducing BRCA1, Fas and FasL Expression in Ovarian Cancer Cells","volume":"1","author":"Cohen","year":"2014","journal-title":"Oncoscience"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/(SICI)1097-0215(19990118)80:2<303::AID-IJC21>3.0.CO;2-W","article-title":"Mesothelial Cells Induce the Motility of Human Ovarian Carcinoma Cells","volume":"80","author":"Rieppi","year":"1999","journal-title":"Int. J. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1479-5876-11-28","article-title":"Mesenchymal Stem Cells Enhance Ovarian Cancer Cell Infiltration through IL6 Secretion in an Amniochorionic Membrane Based 3D Model","volume":"11","author":"Touboul","year":"2013","journal-title":"J. Transl. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1158\/1078-0432.CCR-07-1888","article-title":"Vascular Endothelial Growth Factor Expression in Ovarian Cancer: A Model for Targeted Use of Novel Therapies?","volume":"14","author":"Duncan","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Liao, J., Qian, F., Tchabo, N., Mhawech-Fauceglia, P., Beck, A., Qian, Z., Wang, X., Huss, W.J., Lele, S.B., and Morrison, C.D. (2014). Ovarian Cancer Spheroid Cells with Stem Cell-like Properties Contribute to Tumor Generation, Metastasis and Chemotherapy Resistance through Hypoxia-Resistant Metabolism. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0084941"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.ygyno.2011.02.020","article-title":"MUC16 (CA125) Regulates Epithelial Ovarian Cancer Cell Growth, Tumorigenesis and Metastasis","volume":"121","author":"Pinard","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Lane, D., Matte, I., Rancourt, C., and Pich\u00e9, A. (2011). Prognostic Significance of IL-6 and IL-8 Ascites Levels in Ovarian Cancer Patients. BMC Cancer, 11.","DOI":"10.1186\/1471-2407-11-210"},{"key":"ref_41","first-page":"566","article-title":"Profiling of Cytokines in Human Epithelial Ovarian Cancer Ascites","volume":"2","author":"Matte","year":"2012","journal-title":"Am J. Cancer Res."},{"key":"ref_42","first-page":"1066","article-title":"A Putative New Growth Factor in Ascitic Fluid from Ovarian Cancer Patients: Identification, Characterization, and Mechanism of Action","volume":"48","author":"Mills","year":"1988","journal-title":"Cancer Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1479-5876-2-23","article-title":"Peritoneal Inflammation\u2014A Microenvironment for Epithelial Ovarian Cancer (EOC)","volume":"2","author":"Freedman","year":"2004","journal-title":"J. Transl. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1665-2681(19)30865-8","article-title":"Evaluation of Tumor Markers for the Differential Diagnosis of Benign and Malignant Ascites","volume":"13","author":"Liu","year":"2014","journal-title":"Ann. Hepatol."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Lane, D., Matte, I., Garde-Granger, P., Laplante, C., Carignan, A., Rancourt, C., and Pich\u00e9, A. (2015). Inflammation-Regulating Factors in Ascites as Predictive Biomarkers of Drug Resistance and Progression-Free Survival in Serous Epithelial Ovarian Cancers. BMC Cancer, 15.","DOI":"10.1186\/s12885-015-1511-7"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Matte, I., Garde-Granger, P., Bessette, P., and Pich\u00e9, A. (2019). Ascites from Ovarian Cancer Patients Stimulates MUC16 Mucin Expression and Secretion in Human Peritoneal Mesothelial Cells through an Akt-Dependent Pathway. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-5611-7"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"12394","DOI":"10.1038\/s41598-018-30261-8","article-title":"Inflammation Is a Key Contributor to Ovarian Cancer Cell Seeding","volume":"8","author":"Jia","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"6685","DOI":"10.2147\/CMAR.S179189","article-title":"IL-6 and Ovarian Cancer: Inflammatory Cytokines in Promotion of Metastasis","volume":"10","author":"Browning","year":"2018","journal-title":"Cancer Manag. Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1152\/physrev.00018.2019","article-title":"Immunity, Hypoxia, and Metabolism\u2013the M\u00e9nage \u00e0 Trois of Cancer: Implications for Immunotherapy","volume":"100","author":"Granja","year":"2020","journal-title":"Physiol. Rev."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e17475","DOI":"10.1097\/MD.0000000000017475","article-title":"Prognostic Significance of Neutrophil-Lymphocyte Ratio (NLR) in Patients with Ovarian Cancer: A Systematic Review and Meta-Analysis","volume":"98","author":"Yin","year":"2019","journal-title":"Medicine"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ygyno.2007.02.029","article-title":"Significant Differences of Lymphocytes Isolated from Ascites of Patients with Ovarian Cancer Compared to Blood and Tumor Lymphocytes. Association of CD3+CD56+ Cells with Platinum Resistance","volume":"106","author":"Bamias","year":"2007","journal-title":"Gynecol. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1080\/08820130600803429","article-title":"Dendritic Cells and Tumor Microenvironment: A Dangerous Liaison","volume":"35","author":"Fricke","year":"2006","journal-title":"Immunol. Investig."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"562","DOI":"10.3109\/08820139.2012.685538","article-title":"Negative Regulation of Myeloid-Derived Suppressor Cells in Cancer","volume":"41","author":"Qu","year":"2012","journal-title":"Immunol. Investig."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1097\/IGC.0000000000000672","article-title":"Combined Immunoscore of CD103 and CD3 Identifies Long-Term Survivors in High-Grade Serous Ovarian Cancer","volume":"26","author":"Wagner","year":"2016","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.immuni.2014.06.010","article-title":"Tumor-Associated Macrophages: From Mechanisms to Therapy","volume":"41","author":"Noy","year":"2014","journal-title":"Immunity"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nri2506","article-title":"Myeloid-Derived Suppressor Cells as Regulators of the Immune System","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1007\/s00262-010-0855-8","article-title":"Myeloid-Derived Suppressor Cells: More Mechanisms for Inhibiting Antitumor Immunity","volume":"59","year":"2010","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"678","DOI":"10.4049\/jimmunol.166.1.678","article-title":"Increased Production of Immature Myeloid Cells in Cancer Patients: A Mechanism of Immunosuppression in Cancer","volume":"166","author":"Almand","year":"2001","journal-title":"J. Immunol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/00002371-200111000-00001","article-title":"Tumor-Induced Immune Dysfunctions Caused by Myeloid Suppressor Cells","volume":"24","author":"Bronte","year":"2001","journal-title":"J. Immunother."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1002\/eji.201040895","article-title":"The Biology of Myeloid-Derived Suppressor Cells: The Blessing and the Curse of Morphological and Functional Heterogeneity","volume":"40","author":"Youn","year":"2010","journal-title":"Eur. J. Immunol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1158\/0008-5472.CAN-17-2319","article-title":"Tissue Tranglutaminase Regulates Interactions between Ovarian Cancer Stem Cells and the Tumor Niche","volume":"78","author":"Condello","year":"2018","journal-title":"Cancer Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"5791","DOI":"10.4049\/jimmunol.181.8.5791","article-title":"Subsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice","volume":"181","author":"Youn","year":"2008","journal-title":"J. Immunol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.immuni.2013.08.025","article-title":"Myeloid-Derived Suppressor Cells Enhance Stemness of Cancer Cells by Inducing MicroRNA101 and Suppressing the Corepressor CtBP2","volume":"39","author":"Cui","year":"2013","journal-title":"Immunity"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1158\/1078-0432.CCR-16-0387","article-title":"Expression of Vascular Endothelial Growth Factor in Ovarian Cancer Inhibits Tumor Immunity through the Accumulation of Myeloid-Derived Suppressor Cells","volume":"23","author":"Horikawa","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"76843","DOI":"10.18632\/oncotarget.20164","article-title":"Ascites-Derived IL-6 and IL-10 Synergistically Expand CD14(+)HLA-DR(-\/Low) Myeloid-Derived Suppressor Cells in Ovarian Cancer Patients","volume":"8","author":"Wu","year":"2017","journal-title":"Oncotarget"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s40425-016-0154-9","article-title":"Adenosine-Generating Ovarian Cancer Cells Attract Myeloid Cells Which Differentiate into Adenosine-Generating Tumor Associated Macrophages\u2013A Self-Amplifying, CD39- and CD73-Dependent Mechanism for Tumor Immune Escape","volume":"4","author":"Penski","year":"2016","journal-title":"J. Immunother. Cancer"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1158\/0008-5472.CAN-17-2460","article-title":"Metformin-Induced Reduction of CD39 and CD73 Blocks Myeloid-Derived Suppressor Cell Activity in Patients with Ovarian Cancer","volume":"78","author":"Li","year":"2018","journal-title":"Cancer Res."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"de Sanctis, F., Bronte, V., and Ugel, S. (2016). Tumor-Induced Myeloid-Derived Suppressor Cells. Microbiol. Spectr., 4.","DOI":"10.1128\/microbiolspec.MCHD-0016-2015"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nrc.2016.54","article-title":"The Role of Myeloid Cells in Cancer Therapies","volume":"16","author":"Engblom","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.3389\/fimmu.2019.01084","article-title":"Macrophage Polarization: Different Gene Signatures in M1(LPS+) vs. Classically and M2(LPS-) vs. Alternatively Activated Macrophages","volume":"10","author":"Orecchioni","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1101\/cshperspect.a037044","article-title":"Impact of Immunometabolism on Cancer Metastasis: A Focus on T Cells and Macrophages","volume":"10","author":"Flerin","year":"2020","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.4049\/jimmunol.176.8.5023","article-title":"Ovarian Cancer Cells Polarize Macrophages toward a Tumor-Associated Phenotype","volume":"176","author":"Hagemann","year":"2006","journal-title":"J. Immunol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1182\/blood-2007-02-072587","article-title":"Tumor-Associated Leukemia Inhibitory Factor and IL-6 Skew Monocyte Differentiation into Tumor-Associated Macrophage-like Cells","volume":"110","author":"Duluc","year":"2007","journal-title":"Blood"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1757-2215-7-19","article-title":"A High M1\/M2 Ratio of Tumor-Associated Macrophages Is Associated with Extended Survival in Ovarian Cancer Patients","volume":"7","author":"Zhang","year":"2014","journal-title":"J. Ovarian Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1479-5876-4-30","article-title":"Monocyte\/Macrophage and T-Cell Infiltrates in Peritoneum of Patients with Ovarian Cancer or Benign Pelvic Disease","volume":"4","author":"Wang","year":"2006","journal-title":"J. Transl. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"4157","DOI":"10.1172\/JCI87252","article-title":"Tumor-Associated Macrophages Drive Spheroid Formation during Early Transcoelomic Metastasis of Ovarian Cancer","volume":"126","author":"Yin","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.4049\/jimmunol.175.2.1197","article-title":"Macrophages Induce Invasiveness of Epithelial Cancer Cells via NF-Kappa B and JNK","volume":"175","author":"Hagemann","year":"2005","journal-title":"J. Immunol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"5708","DOI":"10.1158\/0008-5472.CAN-06-4375","article-title":"Macrophages Mediate Inflammation-Enhanced Metastasis of Ovarian Tumors in Mice","volume":"67","author":"Isaacsohn","year":"2007","journal-title":"Cancer Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1089\/lrb.2012.0014","article-title":"Relationships between Lymphangiogenesis and Angiogenesis during Inflammation in Rat Mesentery Microvascular Networks","volume":"10","author":"Sweat","year":"2012","journal-title":"Lymphat. Res. Biol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1073\/pnas.1803999116","article-title":"Suppression of Chemotherapy-Induced Cytokine\/Lipid Mediator Surge and Ovarian Cancer by a Dual COX-2\/SEH Inhibitor","volume":"116","author":"Gartung","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Reader, J., Harper, A.K., Legesse, T., Staats, P.N., Goloubeva, O., Rao, G.G., Fulton, A., and Roque, D.M. (2019). EP4 and Class III \u03b2-Tubulin Expression in Uterine Smooth Muscle Tumors: Implications for Prognosis and Treatment. Cancers, 11.","DOI":"10.3390\/cancers11101590"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"62.e1-9","DOI":"10.1016\/j.ajog.2013.04.017","article-title":"Class III \u03b2-Tubulin Overexpression in Ovarian Clear Cell and Serous Carcinoma as a Maker for Poor Overall Survival after Platinum\/Taxane Chemotherapy and Sensitivity to Patupilone","volume":"209","author":"Roque","year":"2013","journal-title":"Am. J. Obs. Gynecol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s10585-013-9614-5","article-title":"Class III \u03b2-Tubulin Overexpression within the Tumor Microenvironment Is a Prognostic Biomarker for Poor Overall Survival in Ovarian Cancer Patients Treated with Neoadjuvant Carboplatin\/Paclitaxel","volume":"31","author":"Roque","year":"2014","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/nm1093","article-title":"Specific Recruitment of Regulatory T Cells in Ovarian Carcinoma Fosters Immune Privilege and Predicts Reduced Survival","volume":"10","author":"Curiel","year":"2004","journal-title":"Nat. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"8900","DOI":"10.1158\/0008-5472.CAN-07-1866","article-title":"Relationship between B7-H4, Regulatory T Cells, and Patient Outcome in Human Ovarian Carcinoma","volume":"67","author":"Kryczek","year":"2007","journal-title":"Cancer Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1084\/jem.20050930","article-title":"B7-H4 Expression Identifies a Novel Suppressive Macrophage Population in Human Ovarian Carcinoma","volume":"203","author":"Kryczek","year":"2006","journal-title":"J. Exp. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1093\/carcin\/bgs123","article-title":"Tumor-Associated Neutrophils: Friend or Foe?","volume":"33","author":"Fridlender","year":"2012","journal-title":"Carcinogenesis"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.critrevonc.2011.06.004","article-title":"On the Dual Roles and Polarized Phenotypes of Neutrophils in Tumor Development and Progression","volume":"82","author":"Piccard","year":"2012","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.4049\/jimmunol.164.5.2769","article-title":"IL-8 Reduced Tumorigenicity of Human Ovarian Cancer in Vivo Due to Neutrophil Infiltration","volume":"164","author":"Lee","year":"2000","journal-title":"J. Immunol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/j.1365-3083.2008.02139.x","article-title":"Ovarian Cancer Cells Modulate Human Blood Neutrophils Response to Activation in Vitro","volume":"68","author":"Klink","year":"2008","journal-title":"Scand. J. Immunol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"516","DOI":"10.3109\/1354750X.2010.491557","article-title":"Elevated Neutrophil to Lymphocyte Ratio Predicts Survival in Advanced Pancreatic Cancer","volume":"15","author":"An","year":"2010","journal-title":"Biomarkers"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00262-008-0516-3","article-title":"Pre-Treatment Neutrophil to Lymphocyte Ratio Is Elevated in Epithelial Ovarian Cancer and Predicts Survival after Treatment","volume":"58","author":"Cho","year":"2009","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1007\/s00384-010-1052-0","article-title":"Elevated Preoperative Neutrophil to Lymphocyte Ratio Predicts Risk of Recurrence Following Curative Resection for Stage IIA Colon Cancer","volume":"25","author":"Ding","year":"2010","journal-title":"Int. J. Colorectal. Dis."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.ejso.2010.05.004","article-title":"Neutrophil to Lymphocyte Ratio for Preoperative Diagnosis of Uterine Sarcomas: A Case-Matched Comparison","volume":"36","author":"Kim","year":"2010","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/s10120-010-0554-3","article-title":"High Preoperative Neutrophil-Lymphocyte Ratio Predicts Poor Survival in Patients with Gastric Cancer","volume":"13","author":"Shimada","year":"2010","journal-title":"Gastric. Cancer"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1111\/IGC.0b013e3181bb70c6","article-title":"Ovarian Cancer Cells Induce Peripheral Mature Dendritic Cells to Differentiate into Macrophage like Cells in Vitro","volume":"19","author":"Chen","year":"2009","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"5020","DOI":"10.1158\/0008-5472.CAN-04-4043","article-title":"Plasmacytoid Dendritic Cells Induce CD8+ Regulatory T Cells in Human Ovarian Carcinoma","volume":"65","author":"Wei","year":"2005","journal-title":"Cancer Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"5535","DOI":"10.1158\/0008-5472.CAN-04-1272","article-title":"Dendritic Cell Subsets Differentially Regulate Angiogenesis in Human Ovarian Cancer","volume":"64","author":"Curiel","year":"2004","journal-title":"Cancer Res."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"7684","DOI":"10.1158\/0008-5472.CAN-08-1167","article-title":"Depletion of Dendritic Cells Delays Ovarian Cancer Progression by Boosting Antitumor Immunity","volume":"68","author":"Huarte","year":"2008","journal-title":"Cancer Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"5423","DOI":"10.1158\/0008-5472.CAN-11-0367","article-title":"Quantitative and Functional Alterations of Plasmacytoid Dendritic Cells Contribute to Immune Tolerance in Ovarian Cancer","volume":"71","author":"Sisirak","year":"2011","journal-title":"Cancer Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"380","DOI":"10.4161\/onci.18801","article-title":"Plasmacytoid Dendritic Cells Infiltrating Ovarian Cancer Are Associated with Poor Prognosis","volume":"1","author":"Treilleux","year":"2012","journal-title":"Oncoimmunology"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"3156","DOI":"10.3389\/fimmu.2018.03156","article-title":"Survival of Ovarian Cancer Patients Is Independent of the Presence of DC and T Cell Subsets in Ascites","volume":"9","author":"Wefers","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Brencicova, E., Jagger, A.L., Evans, H.G., Georgouli, M., Laios, A., Attard Montalto, S., Mehra, G., Spencer, J., Ahmed, A.A., and Raju-Kankipati, S. (2017). Interleukin-10 and Prostaglandin E2 Have Complementary but Distinct Suppressive Effects on Toll-like Receptor-Mediated Dendritic Cell Activation in Ovarian Carcinoma. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0175712"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/ni.3518","article-title":"Targeting Natural Killer Cells in Cancer Immunotherapy","volume":"17","author":"Guillerey","year":"2016","journal-title":"Nat. Immunol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1615\/CritRevOncog.2014010805","article-title":"Positive and Negative Regulation by NK Cells in Cancer","volume":"19","author":"Sungur","year":"2014","journal-title":"Crit. Rev. Oncog."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1309\/15B66DQMFYYM78CJ","article-title":"NK- and B-Cell Infiltration Correlates with Worse Outcome in Metastatic Ovarian Carcinoma","volume":"125","author":"Dong","year":"2006","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1158\/1078-0432.CCR-13-1877","article-title":"Tumor-Infiltrating Lymphocytes Expressing the Tissue Resident Memory Marker CD103 Are Associated with Increased Survival in High-Grade Serous Ovarian Cancer","volume":"20","author":"Webb","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1159\/000292678","article-title":"Natural Killer Cell Activity and Progression-Free Survival in Ovarian Cancer","volume":"35","author":"Garzetti","year":"1993","journal-title":"Gynecol. Obs. Investig."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00262-008-0585-3","article-title":"Clinical Significance of the NKG2D Ligands, MICA\/B and ULBP2 in Ovarian Cancer: High Expression of ULBP2 Is an Indicator of Poor Prognosis","volume":"58","author":"Li","year":"2009","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"e13284","DOI":"10.1111\/aji.13284","article-title":"Identification of Unique Clusters of T, Dendritic, and Innate Lymphoid Cells in the Peritoneal Fluid of Ovarian Cancer Patients","volume":"84","author":"Vazquez","year":"2020","journal-title":"Am. J. Reprod. Immunol."},{"key":"ref_112","first-page":"161","article-title":"Alterations in Expression and Function of Signal-Transducing Proteins in Tumor-Associated T and Natural Killer Cells in Patients with Ovarian Carcinoma","volume":"2","author":"Lai","year":"1996","journal-title":"Clin. Cancer Res."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"4120","DOI":"10.1073\/pnas.0730640100","article-title":"Transforming Growth Factor Beta 1 Inhibits Expression of NKp30 and NKG2D Receptors: Consequences for the NK-Mediated Killing of Dendritic Cells","volume":"100","author":"Castriconi","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Greppi, M., Tabellini, G., Patrizi, O., Candiani, S., Decensi, A., Parolini, S., Sivori, S., Pesce, S., Paleari, L., and Marcenaro, E. (2019). Strengthening the AntiTumor NK Cell Function for the Treatment of Ovarian Cancer. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20040890"},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Rodriguez, G., Galpin, K., McCloskey, C., and Vanderhyden, B. (2018). The Tumor Microenvironment of Epithelial Ovarian Cancer and Its Influence on Response to Immunotherapy. Cancers, 10.","DOI":"10.3390\/cancers10080242"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s00262-017-2112-x","article-title":"Ex Vivo-Expanded NK Cells from Blood and Ascites of Ovarian Cancer Patients Are Cytotoxic against Autologous Primary Ovarian Cancer Cells","volume":"67","author":"Nham","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1080\/15384047.2015.1040960","article-title":"Tumor Infiltrating Lymphocytes in Ovarian Cancer","volume":"16","author":"Santoiemma","year":"2015","journal-title":"Cancer Biol. Ther."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ygyno.2018.09.005","article-title":"Tumor-Infiltrating T Cells in Epithelial Ovarian Cancer: Predictors of Prognosis and Biological Basis of Immunotherapy","volume":"151","author":"Wang","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1038\/sj.bjc.6605274","article-title":"Intraepithelial CD8-Positive T Lymphocytes Predict Survival for Patients with Serous Stage III Ovarian Carcinomas: Relevance of Clonal Selection of T Lymphocytes","volume":"101","author":"Stumpf","year":"2009","journal-title":"Br. J. Cancer"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00262-008-0583-5","article-title":"Prognostic Significance of Tumor-Infiltrating T-Lymphocytes in Primary and Metastatic Lesions of Advanced Stage Ovarian Cancer","volume":"58","author":"Leffers","year":"2009","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1093\/annonc\/mdi112","article-title":"Tumour-Infiltrating Gamma\/Delta T-Lymphocytes Are Correlated with a Brief Disease-Free Interval in Advanced Ovarian Serous Carcinoma","volume":"16","author":"Raspollini","year":"2005","journal-title":"Ann. Oncol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ygyno.2007.10.016","article-title":"Prognostic Significance of CD3+ Tumor-Infiltrating Lymphocytes in Ovarian Carcinoma","volume":"108","author":"Melichar","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1158\/1078-0432.CCR-12-0234","article-title":"CD20+ Tumor-Infiltrating Lymphocytes Have an Atypical CD27- Memory Phenotype and Together with CD8+ T Cells Promote Favorable Prognosis in Ovarian Cancer","volume":"18","author":"Nielsen","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.ygyno.2009.11.020","article-title":"Ovarian Cancer Tumor Infiltrating T-Regulatory (T(Reg)) Cells Are Associated with a Metastatic Phenotype","volume":"116","author":"Barnett","year":"2010","journal-title":"Gynecol. Oncol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.clim.2011.08.013","article-title":"The Comprehensive Assessment of Local Immune Status of Ovarian Cancer by the Clustering of Multiple Immune Factors","volume":"141","author":"Hamanishi","year":"2011","journal-title":"Clin. Immunol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ygyno.2011.09.039","article-title":"Prognostic Significance of Tumor-Infiltrating T Cells in Ovarian Cancer: A Meta-Analysis","volume":"124","author":"Hwang","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"ref_127","first-page":"263","article-title":"Tumor-Infiltrating Lymphocytes from Human Ovarian Cancer Patients Recognize Autologous Tumor in an MHC Class II-Restricted Fashion","volume":"2","author":"Dadmarz","year":"1996","journal-title":"Cancer J. Sci. Am."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa020177","article-title":"Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer","volume":"348","author":"Zhang","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1002\/ijc.27759","article-title":"Dynamics of T-Cell Infiltration during the Course of Ovarian Cancer: The Gradual Shift from a Th17 Effector Cell Response to a Predominant Infiltration by Regulatory T-Cells","volume":"132","author":"Sojka","year":"2013","journal-title":"Int. J. Cancer"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"18538","DOI":"10.1073\/pnas.0509182102","article-title":"Intraepithelial CD8+ Tumor-Infiltrating Lymphocytes and a High CD8+\/Regulatory T Cell Ratio Are Associated with Favorable Prognosis in Ovarian Cancer","volume":"102","author":"Sato","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"e1090075","DOI":"10.1080\/2162402X.2015.1090075","article-title":"Anti-CCR4 Monoclonal Antibody Enhances Antitumor Immunity by Modulating Tumor-Infiltrating Tregs in an Ovarian Cancer Xenograft Humanized Mouse Model","volume":"5","author":"Chang","year":"2016","journal-title":"Oncoimmunology"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"75130","DOI":"10.18632\/oncotarget.12077","article-title":"CD103+ Intraepithelial T Cells in High-Grade Serous Ovarian Cancer Are Phenotypically Diverse TCR\u03b1\u03b2+ CD8\u03b1\u03b2+ T Cells That Can Be Targeted for Cancer Immunotherapy","volume":"7","author":"Komdeur","year":"2016","journal-title":"Oncotarget"},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Preston, C.C., Maurer, M.J., Oberg, A.L., Visscher, D.W., Kalli, K.R., Hartmann, L.C., Goode, E.L., and Knutson, K.L. (2013). The Ratios of CD8+ T Cells to CD4+CD25+ FOXP3+ and FOXP3- T Cells Correlate with Poor Clinical Outcome in Human Serous Ovarian Cancer. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0080063"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/bjc.2016.172","article-title":"CXCL9 and CXCL10 Predict Survival and Are Regulated by Cyclooxygenase Inhibition in Advanced Serous Ovarian Cancer","volume":"115","author":"Bronger","year":"2016","journal-title":"Br. J. Cancer"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/modpathol.2008.187","article-title":"Classification Using Hierarchical Clustering of Tumor-Infiltrating Immune Cells Identifies Poor Prognostic Ovarian Cancers with High Levels of COX Expression","volume":"22","author":"Liu","year":"2009","journal-title":"Mod. Pathol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1158\/1078-0432.CCR-07-4433","article-title":"HLA Class I Antigen Processing Machinery Component Expression and Intratumoral T-Cell Infiltrate as Independent Prognostic Markers in Ovarian Carcinoma","volume":"14","author":"Han","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/modpathol.2008.191","article-title":"Intraepithelial T Cells and Prognosis in Ovarian Carcinoma: Novel Associations with Stage, Tumor Type, and BRCA1 Loss","volume":"22","author":"Clarke","year":"2009","journal-title":"Mod. Pathol."},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Hermans, C., Anz, D., Engel, J., Kirchner, T., Endres, S., and Mayr, D. (2014). Analysis of FoxP3+ T-Regulatory Cells and CD8+T-Cells in Ovarian Carcinoma: Location and Tumor Infiltration Patterns Are Key Prognostic Markers. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0111757"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ygyno.2009.11.005","article-title":"Characterization of Humoral Responses of Ovarian Cancer Patients: Antibody Subclasses and Antigenic Components","volume":"116","author":"Taylor","year":"2010","journal-title":"Gynecol. Oncol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1586\/14737159.2015.1035713","article-title":"Tumor Associated Antigens or Anti-TAA Autoantibodies as Biomarkers in the Diagnosis of Ovarian Cancer: A Systematic Review with Meta-Analysis","volume":"15","author":"Shi","year":"2015","journal-title":"Expert Rev. Mol. Diagn."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ygyno.2009.06.031","article-title":"Patient-Derived Tumor-Reactive Antibodies as Diagnostic Markers for Ovarian Cancer","volume":"115","author":"Taylor","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"e1030561","DOI":"10.1080\/2162402X.2015.1030561","article-title":"Characterization of T Cell Repertoire of Blood, Tumor, and Ascites in Ovarian Cancer Patients Using Next Generation Sequencing","volume":"4","author":"Jang","year":"2015","journal-title":"Oncoimmunology"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"e1371895","DOI":"10.1080\/2162402X.2017.1371895","article-title":"A Library-Based Screening Method Identifies Neoantigen-Reactive T Cells in Peripheral Blood Prior to Relapse of Ovarian Cancer","volume":"7","author":"Martin","year":"2017","journal-title":"Oncoimmunology"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00262-014-1636-6","article-title":"Activated Regulatory and Memory T-Cells Accumulate in Malignant Ascites from Ovarian Carcinoma Patients","volume":"64","author":"Landskron","year":"2015","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_145","first-page":"290","article-title":"Comparative Study of Various Subpopulations of Cytotoxic Cells in Blood and Ascites from Patients with Ovarian Carcinoma","volume":"19","author":"Lukesova","year":"2015","journal-title":"Contemp. Oncol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/nm.4241","article-title":"T Memory Stem Cells in Health and Disease","volume":"23","author":"Gattinoni","year":"2017","journal-title":"Nat. Med."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1084\/jem.186.9.1407","article-title":"Phenotypic and Functional Separation of Memory and Effector Human CD8+ T Cells","volume":"186","author":"Hamann","year":"1997","journal-title":"J. Exp. Med."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/44385","article-title":"Two Subsets of Memory T Lymphocytes with Distinct Homing Potentials and Effector Functions","volume":"401","author":"Sallusto","year":"1999","journal-title":"Nature"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/ni.3415","article-title":"Emerging Concepts of T Cell Metabolism as a Target of Immunotherapy","volume":"17","author":"Chang","year":"2016","journal-title":"Nat. Immunol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/ni.2687","article-title":"Rapid Effector Function of Memory CD8+ T Cells Requires an Immediate-Early Glycolytic Switch","volume":"14","author":"Gubser","year":"2013","journal-title":"Nat. Immunol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.coi.2017.03.011","article-title":"Metabolic Reprograming of Anti-Tumor Immunity","volume":"46","author":"Sukumar","year":"2017","journal-title":"Curr. Opin. Immunol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"4479","DOI":"10.1172\/JCI69589","article-title":"Inhibiting Glycolytic Metabolism Enhances CD8+ T Cell Memory and Antitumor Function","volume":"123","author":"Sukumar","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_153","first-page":"2875","article-title":"Ovarian Cancer-Associated Ascites Demonstrates Altered Immune Environment-2009","volume":"29","author":"Giuntoli","year":"2009","journal-title":"Anticancer Res."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1073\/pnas.0712237105","article-title":"Immunologic and Clinical Effects of Antibody Blockade of Cytotoxic T Lymphocyte-Associated Antigen 4 in Previously Vaccinated Cancer Patients","volume":"105","author":"Hodi","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"7875","DOI":"10.1073\/pnas.1003345107","article-title":"Tumor-Infiltrating NY-ESO-1-Specific CD8+ T Cells Are Negatively Regulated by LAG-3 and PD-1 in Human Ovarian Cancer","volume":"107","author":"Matsuzaki","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1200\/JCO.2015.62.3397","article-title":"Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer","volume":"33","author":"Hamanishi","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"27359","DOI":"10.18632\/oncotarget.4751","article-title":"LAG3 and PD1 Co-Inhibitory Molecules Collaborate to Limit CD8+ T Cell Signaling and Dampen Antitumor Immunity in a Murine Ovarian Cancer Model","volume":"6","author":"Huang","year":"2015","journal-title":"Oncotarget"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature21349","article-title":"Elements of Cancer Immunity and the Cancer-Immune Set Point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"328rv4","DOI":"10.1126\/scitranslmed.aad7118","article-title":"PD-L1 (B7-H1) and PD-1 Pathway Blockade for Cancer Therapy: Mechanisms, Response Biomarkers, and Combinations","volume":"8","author":"Zou","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1158\/1078-0432.CCR-12-2199","article-title":"PD-L1 on Tumor Cells Is Induced in Ascites and Promotes Peritoneal Dissemination of Ovarian Cancer through CTL Dysfunction","volume":"19","author":"Abiko","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/cddis.2015.162","article-title":"T-Cell Exhaustion in the Tumor Microenvironment","volume":"6","author":"Jiang","year":"2015","journal-title":"Cell Death Dis."},{"key":"ref_162","first-page":"14","article-title":"Human Ovarian Tumor Ascites Fluids Rapidly and Reversibly Inhibit T Cell Receptor-Induced NF-\u039aB and NFAT Signaling in Tumor-Associated T Cells","volume":"13","author":"Loyall","year":"2013","journal-title":"Cancer Immun."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"e1424672","DOI":"10.1080\/2162402X.2018.1424672","article-title":"Prognosis of Ovarian Cancer Is Associated with Effector Memory CD8 + T Cell Accumulation in Ascites, CXCL9 Levels and Activation-Triggered Signal Transduction in T Cells","volume":"7","author":"Lieber","year":"2018","journal-title":"OncoImmunology"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1136\/bmj.321.7258.424","article-title":"Th1 and Th2 Responses: What Are They?","volume":"321","author":"Berger","year":"2000","journal-title":"BMJ"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ccr.2009.06.018","article-title":"CD4(+) T Cells Regulate Pulmonary Metastasis of Mammary Carcinomas by Enhancing Protumor Properties of Macrophages","volume":"16","author":"DeNardo","year":"2009","journal-title":"Cancer Cell"},{"key":"ref_166","first-page":"791603","article-title":"Immune Response in Ovarian Cancer: How Is the Immune System Involved in Prognosis and Therapy: Potential for Treatment Utilization","volume":"2010","author":"Gavalas","year":"2010","journal-title":"Clin. Dev. Immunol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/nature07036","article-title":"Induction and Effector Functions of T(H)17 Cells","volume":"453","author":"Bettelli","year":"2008","journal-title":"Nature"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1182\/blood-2009-03-208249","article-title":"Phenotype, Distribution, Generation, and Functional and Clinical Relevance of Th17 Cells in the Human Tumor Environments","volume":"114","author":"Kryczek","year":"2009","journal-title":"Blood"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/CJI.0b013e318195b59e","article-title":"Interleukin 2-Mediated Conversion of Ovarian Cancer-Associated CD4+ Regulatory T Cells into Proinflammatory Interleukin 17-Producing Helper T Cells","volume":"32","author":"Leveque","year":"2009","journal-title":"J. Immunother."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00005-010-0075-0","article-title":"Regulatory T Cell as a Target for Cancer Therapy","volume":"58","author":"Silva","year":"2010","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"15505","DOI":"10.1073\/pnas.0710686105","article-title":"Generation and Regulation of Human CD4+ IL-17-Producing T Cells in Ovarian Cancer","volume":"105","author":"Miyahara","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nature10169","article-title":"Tumour Hypoxia Promotes Tolerance and Angiogenesis via CCL28 and T(Reg) Cells","volume":"475","author":"Facciabene","year":"2011","journal-title":"Nature"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.it.2012.01.002","article-title":"Regulatory T Cell Migration during an Immune Response","volume":"33","author":"Ding","year":"2012","journal-title":"Trends Immunol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.humimm.2014.12.004","article-title":"Clinical Relevance of Regulatory T Cells Monitoring in the Peripheral Blood of Ovarian Cancer Patients","volume":"76","author":"Rob","year":"2015","journal-title":"Hum. Immunol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3109\/08820139.2010.513022","article-title":"Circulating Regulatory T Cells in Endometrial Cancer: A Role for Age and Menopausal Status","volume":"40","author":"Sawan","year":"2011","journal-title":"Immunol. Investig."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"4811","DOI":"10.1007\/s13277-015-3133-8","article-title":"Macrophage-Derived Chemokine CCL22 and Regulatory T Cells in Ovarian Cancer Patients","volume":"36","author":"Wertel","year":"2015","journal-title":"Tumour Biol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"4351","DOI":"10.1158\/0008-5472.CAN-12-0579","article-title":"CXCR3+ T Regulatory Cells Selectively Accumulate in Human Ovarian Carcinomas to Limit Type I Immunity","volume":"72","author":"Redjimi","year":"2012","journal-title":"Cancer Res."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1080\/08820139.2016.1186689","article-title":"Minireview: Regulatory T Cells and Ovarian Cancer","volume":"45","author":"Singh","year":"2016","journal-title":"Immunol. Investig."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"3949","DOI":"10.1007\/s13277-015-4237-x","article-title":"Ovarian Carcinoma-Infiltrating Regulatory T Cells Were More Potent Suppressors of CD8(+) T Cell Inflammation than Their Peripheral Counterparts, a Function Dependent on TIM3 Expression","volume":"37","author":"Bu","year":"2016","journal-title":"Tumour Biol."},{"key":"ref_180","doi-asserted-by":"crossref","unstructured":"Chen, Y.-L., Chang, M.-C., Chen, C.-A., Lin, H.-W., Cheng, W.-F., and Chien, C.-L. (2012). Depletion of Regulatory T Lymphocytes Reverses the Imbalance between Pro- and Anti-Tumor Immunities via Enhancing Antigen-Specific T Cell Immune Responses. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0047190"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"345164","DOI":"10.1155\/2012\/345164","article-title":"Regulatory T Cells in Human Ovarian Cancer","volume":"2012","author":"Peng","year":"2012","journal-title":"J. Oncol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.1600-0897.2011.01068.x","article-title":"Distinct Subpopulations of Epithelial Ovarian Cancer Cells Can Differentially Induce Macrophages and T Regulatory Cells toward a Pro-Tumor Phenotype","volume":"67","author":"Alvero","year":"2012","journal-title":"Am. J. Reprod. Immunol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/j.ejca.2011.03.026","article-title":"Cytokine Analysis as a Tool to Understand Tumour-Host Interaction in Ovarian Cancer","volume":"47","author":"Yigit","year":"2011","journal-title":"Eur. J. Cancer"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/S0002-9440(10)65669-6","article-title":"Role of Vascular Endothelial Growth Factor in Ovarian Cancer: Inhibition of Ascites Formation by Immunoneutralization","volume":"153","author":"Mesiano","year":"1998","journal-title":"Am. J. Pathol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/s41568-021-00363-z","article-title":"Interleukins in Cancer: From Biology to Therapy","volume":"21","author":"Briukhovetska","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/(SICI)1097-0215(19961104)68:3<276::AID-IJC2>3.0.CO;2-Z","article-title":"Expression of Cytokine Genes or Proteins and Signaling Molecules in Lymphocytes Associated with Human Ovarian Carcinoma","volume":"68","author":"Rabinowich","year":"1996","journal-title":"Int. J. Cancer"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"a028472","DOI":"10.1101\/cshperspect.a028472","article-title":"Cytokines in Cancer Immunotherapy","volume":"10","author":"Waldmann","year":"2018","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"108515","DOI":"10.1016\/j.clim.2020.108515","article-title":"The IL-2 - IL-2 Receptor Pathway in Health and Disease: The Role of the Soluble IL-2 Receptor","volume":"218","author":"Damoiseaux","year":"2020","journal-title":"Clin. Immunol."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ijgo.2003.08.015","article-title":"Interleukin-7 and Suppression of Local Peritoneal Immunity in Ovarian Carcinoma","volume":"85","author":"Xie","year":"2004","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"e20190297","DOI":"10.1084\/jem.20190297","article-title":"The Role of Interleukin-17 in Tumor Development and Progression","volume":"217","author":"Zhao","year":"2019","journal-title":"J. Exp. Med."},{"key":"ref_191","doi-asserted-by":"crossref","unstructured":"Vitiello, G.A., and Miller, G. (2020). Targeting the Interleukin-17 Immune Axis for Cancer Immunotherapy. J. Exp. Med., 217.","DOI":"10.1084\/jem.20190456"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1159\/000055357","article-title":"Inoculation of Human Interleukin-17 Gene-Transfected Meth-A Fibrosarcoma Cells Induces T Cell-Dependent Tumor-Specific Immunity in Mice","volume":"61","author":"Hirahara","year":"2001","journal-title":"Oncology"},{"key":"ref_193","first-page":"24","article-title":"T Lymphocytes and Cytokine Production in Ascitic Fluid of Ovarian Malignancies","volume":"98","author":"Chen","year":"1999","journal-title":"J. Formos. Med. Assoc."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.immuni.2019.03.012","article-title":"Interleukin-1 and Related Cytokines in the Regulation of Inflammation and Immunity","volume":"50","author":"Mantovani","year":"2019","journal-title":"Immunity"},{"key":"ref_195","doi-asserted-by":"crossref","unstructured":"Gottschlich, A., Endres, S., and Kobold, S. (2021). Therapeutic Strategies for Targeting IL-1 in Cancer. Cancers, 13.","DOI":"10.3390\/cancers13030477"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41577-018-0066-7","article-title":"Recent Insights into Targeting the IL-6 Cytokine Family in Inflammatory Diseases and Cancer","volume":"18","author":"Jones","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/intimm\/dxaa078","article-title":"IL-6 in Inflammation, Autoimmunity and Cancer","volume":"33","author":"Hirano","year":"2021","journal-title":"Int. Immunol."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"a028415","DOI":"10.1101\/cshperspect.a028415","article-title":"Interleukin-6 Family Cytokines","volume":"10","year":"2018","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_199","first-page":"1715","article-title":"Expression of IL-10 in Patients with Ovarian Carcinoma","volume":"26","author":"Mustea","year":"2006","journal-title":"Anticancer Res."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.immuni.2019.03.020","article-title":"IL-10 Family Cytokines IL-10 and IL-22: From Basic Science to Clinical Translation","volume":"50","author":"Ouyang","year":"2019","journal-title":"Immunity"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.ccell.2018.10.007","article-title":"PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8(+) T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients","volume":"34","author":"Naing","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3389\/fimmu.2011.00029","article-title":"IL-10 Immunomodulation of Myeloid Cells Regulates a Murine Model of Ovarian Cancer","volume":"2","author":"Hart","year":"2011","journal-title":"Front. Immunol."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S1359-6101(03)00003-0","article-title":"TGF-beta: The missing link in CD4+CD25+ regulatory T cell-mediated immunosuppression","volume":"14","author":"Chen","year":"2003","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_204","first-page":"95","article-title":"Transforming growth factor-beta inhibits the in vitro generation of lymphokine-activated killer cells and cytotoxic T cells","volume":"26","author":"Schwarz","year":"1988","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.4049\/jimmunol.170.7.3806","article-title":"Tumor-derived TGF-beta reduces the efficacy of dendritic cell\/tumor fusion vaccine","volume":"170","author":"Kao","year":"2003","journal-title":"J. Immunol."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1093\/jnci\/djn024","article-title":"Effect of Interleukin-8 Gene Silencing with Liposome-Encapsulated Small Interfering RNA on Ovarian Cancer Cell Growth","volume":"100","author":"Merritt","year":"2008","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/s41591-020-0873-9","article-title":"IL-8 and Cancer Prognosis on Immunotherapy","volume":"26","author":"Bakouny","year":"2020","journal-title":"Nat. Med."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"4478","DOI":"10.1158\/0008-5472.CAN-05-3825","article-title":"Adoptive Transfer of Type 1 CTL Mediates Effective Anti-Central Nervous System Tumor Response: Critical Roles of IFN-Inducible Protein-10","volume":"66","author":"Nishimura","year":"2006","journal-title":"Cancer Res."},{"key":"ref_209","first-page":"199","article-title":"Intratumoral Expression of MIP-1beta Induces Antitumor Responses in a Pre-Established Tumor Model through Chemoattracting T Cells and NK Cells","volume":"1","author":"Luo","year":"2004","journal-title":"Cell. Mol. Immunol."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"9417","DOI":"10.1158\/0008-5472.CAN-07-1286","article-title":"Targeting CCL2 with Systemic Delivery of Neutralizing Antibodies Induces Prostate Cancer Tumor Regression in Vivo","volume":"67","author":"Loberg","year":"2007","journal-title":"Cancer Res."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.ygyno.2006.01.029","article-title":"Elevated Serum RANTES Levels in Patients with Ovarian Cancer Correlate with the Extent of the Disorder","volume":"102","author":"Tsukishiro","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.4161\/cbt.6.12.4976","article-title":"PDGF BB Induces VEGF Secretion in Ovarian Cancer","volume":"6","author":"Matei","year":"2007","journal-title":"Cancer Biol. Ther."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1054\/bjoc.2000.1228","article-title":"Prognostic Significance of Vascular Endothelial Growth Factor Expression in Human Ovarian Carcinoma","volume":"83","author":"Shen","year":"2000","journal-title":"Br. J. Cancer"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2007.11.5345","article-title":"Phase II Trial of Bevacizumab in Persistent or Recurrent Epithelial Ovarian Cancer or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study","volume":"25","author":"Burger","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1007\/s13238-017-0466-7","article-title":"Revisiting Ovarian Cancer Microenvironment: A Friend or a Foe?","volume":"9","author":"Zhang","year":"2018","journal-title":"Protein Cell"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/18\/10692\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:31:17Z","timestamp":1760142677000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/18\/10692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,14]]},"references-count":215,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["ijms231810692"],"URL":"https:\/\/doi.org\/10.3390\/ijms231810692","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,14]]}}}